LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Oxford University Press
Languages: English
Types: Article
Subjects:

Classified by OpenAIRE into

mesheuropmc: musculoskeletal diseases, nutritional and metabolic diseases, congenital, hereditary, and neonatal diseases and abnormalities
Objective: To examine the association between allopurinol use and all-cause mortality for patients with incident gout.\ud \ud Methods: We compared all-cause mortality in incident gout patients who received allopurinol for at least 6 months within the exposure window (1 year or 3 years) with those who did not, using the UK Clinical Practice Research Data-link. Landmark analysis was used to account for immortal time bias and propensity score matching was used to control for potential effects of known confounders.\ud \ud Results: Of 23 332 incident gout patients identified, the propensity score–matched cohorts contained 1016 patients exposed to allopurinol on the date 1 year from diagnosis (landmark date) and 1016 allopurinol non-users. Over a median follow-up period of 10 years after the landmark date, there were 437 allopurinol users and 443 allopurinol non-users who died during follow-up. Allopurinol users and non-users had similar risk for all-cause mortality (hazard ratio 0.99; 95% CI 0.87, 1.12). In the 3-year landmark analysis, 3519 allopurinol users (1280 died) were compared with 3519 non-users (1265 died). The hazard ratio for all-cause mortality was 1.01 (95% CI 0.92, 1.09).\ud \ud Conclusion: This propensity score–matched landmark analysis in a population of incident gout patients in the UK primary care setting found a neutral effect on the risk of all-cause mortality. Our study provides reassurance about the prescription of allopurinol for gout patients early in their disease course to prevent untoward consequences of chronic uncontrolled hyperuricaemia. However, whether higher than the commonly used dose of allopurinol could influence mortality remains to be determined.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443 9.
    • 2 Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301 11.
    • 3 Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis 2014; Advance Access published 14 November 2014, doi: 10.1136/annrheumdis-2014-206410.
    • 4 Kuo CF, Yu KH, See LC et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine 2011;78:577 80.
    • 5 Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA 2014;312:2684 6.
    • 6 Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev 2011;19:265 71.
    • 7 Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58:25 32.
    • 8 Doherty M, Jansen TL, Nuki G et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765 70.
    • 9 Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4 14.
    • 10 Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015;74:661 7.
    • 11 Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol 1997;44:175 8.
    • 12 Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011;4:363 71.
    • 13 Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41 55.
    • 14 Weiss GB, Bunce H III, Hokanson JA. Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. Control Clin Trials 1983;4:43 52.
    • 15 Malek F, Ostadal P, Parenica J et al. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure-results of the Acute HEart FAilure Database registry. J Crit Care 2012;27:737 e11 24.
    • 16 Wu AH, Ghali JK, Neuberg GW et al. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 2010;160:928 33.
    • 17 Luk AJ, Levin GP, Moore EE et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology 2009;48:804 6.
    • 18 Struthers AD, Donnan PT, Lindsay P et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229 34.
    • 19 Dubreuil M, Zhu Y, Zhang Y et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2015;74:1368 72.
    • 20 Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology 2010;49:105 11.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article